ArticleFrontiers in allergy2022

Real-Life Experience With Subcutaneous Plasma-Derived C1-Inhibitor for Long-Term Prophylaxis in Patients With Hereditary Angioedema: A Case Series.

Andrea Zanichelli et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.